We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ResMed Inc. (RMD - Free Report) announced second-quarter fiscal 2020 results, wherein adjusted earnings per share (EPS) were $1.21, up 21% year over year. The metric also beat the Zacks Consensus Estimate by 19.8%.
On a GAAP (reported) basis, EPS was $1.10 for the quarter under review, reflecting an increase of 27.9% from the year-ago period.
Second-quarter revenues, on a reported basis, increased 13.1% year over year (up 14% at constant exchange rate or CER) to $736.2 million. The figure surpassed the Zacks Consensus Estimate by 1.5%.
Non-GAAP revenues (adding back fair value adjustment of deferred revenues) were $736.8 million, reflecting an improvement of 12.8% from the year-ago adjusted figure.
Geographically, excluding Software-as-a-Service, revenues in the United States, Canada and Latin America improved 14% from the prior-year period to $408 million on the robust performance of its mask and device product portfolios.
Global revenues from Software-as-a-Service in the quarter under review summed $86.7 million, representing a 37% increase year over year.
Revenues in combined Europe, Asia and other markets were $241.5 million, highlighting an 8% rise at CER from the year-earlier number.
Margins
Gross margin for the fiscal second quarter was 59.7%, reflecting a 72-basis point (bps) expansion from the year-ago number. The expansion was fueled by benefits from changes in the product mix, and manufacturing and procurement efficiencies.
Selling, general and administrative expenses were up 6.1% year over year to $171.4 million (up by 8% at constant exchange rate or CER). However, excluding the effects of recent acquisitions, the metric rose to 23.3% year over year (or up 2% at CER).
Research and development expenses increased 15.8% to $49.9 million (up 18% at CER). This, in turn, increased adjusted operating expenses by 8.1%, which amounted to $221.4 million. However, adjusted operating margin in the reported quarter expanded 209 bps to 29.6%.
Financial Updates
ResMed exited the second quarter of fiscal 2020 with cash and cash equivalents of $204.1 million compared with $172.2 million at the end of the first quarter.
Cumulative cash flow from operating activities was $232.3 million at the end of the second quarter compared with $177.6 million in the year-ago period.
Along with the earnings release, ResMed announced a regular quarterly dividend payout of 39 cents per share.
Our Take
The company exited second-quarter fiscal 2020 on a solid note, with earnings and revenues beating the Zacks Consensus Estimate. It is encouraging to note that ResMed registered growth at CER across both its key operating segments — Total Sleep and Respiratory Care, and Software-as-a-Service.
Mask sales were particularly strong in Europe and Asia. Within Software-as-a-Service, the company recorded continued momentum in the Brightree service portfolio and an additional contribution from the MatrixCare buyout.
However, in the quarter, device sales in France were impacted as customers completed their connected device upgrade programs.
The Zacks Consensus Estimate for SeaSpine’s fourth-quarter 2019 revenues is pegged at $43.6 million, suggesting 14.7% growth from the prior-year reported figure. The same for loss per share is anticipated at 44 cents, implying a 16.9% improvement from the year-ago reported number.
The Zacks Consensus Estimate for STERIS’s third-quarter fiscal 2020 revenues is pegged at $749.7 million, hinting at a 7.7% increase from the year-earlier reported figure. The same for adjusted earnings per share stands at $1.43, indicating a 13.5% rise from the year-ago reported figure.
The Zacks Consensus Estimate for DexCom’s fourth-quarter 2019 revenues is pegged at $457 million, suggesting 35.2% growth from the prior-year reported figure. The same for adjusted earnings per share stands at 72 cents, implying a 33.3% improvement from the year-earlier reported figure.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand
ResMed Inc. (RMD - Free Report) announced second-quarter fiscal 2020 results, wherein adjusted earnings per share (EPS) were $1.21, up 21% year over year. The metric also beat the Zacks Consensus Estimate by 19.8%.
On a GAAP (reported) basis, EPS was $1.10 for the quarter under review, reflecting an increase of 27.9% from the year-ago period.
Second-quarter revenues, on a reported basis, increased 13.1% year over year (up 14% at constant exchange rate or CER) to $736.2 million. The figure surpassed the Zacks Consensus Estimate by 1.5%.
Non-GAAP revenues (adding back fair value adjustment of deferred revenues) were $736.8 million, reflecting an improvement of 12.8% from the year-ago adjusted figure.
ResMed Inc. Price, Consensus and EPS Surprise
ResMed Inc. price-consensus-eps-surprise-chart | ResMed Inc. Quote
A Closer View of the Top Line
Geographically, excluding Software-as-a-Service, revenues in the United States, Canada and Latin America improved 14% from the prior-year period to $408 million on the robust performance of its mask and device product portfolios.
Global revenues from Software-as-a-Service in the quarter under review summed $86.7 million, representing a 37% increase year over year.
Revenues in combined Europe, Asia and other markets were $241.5 million, highlighting an 8% rise at CER from the year-earlier number.
Margins
Gross margin for the fiscal second quarter was 59.7%, reflecting a 72-basis point (bps) expansion from the year-ago number. The expansion was fueled by benefits from changes in the product mix, and manufacturing and procurement efficiencies.
Selling, general and administrative expenses were up 6.1% year over year to $171.4 million (up by 8% at constant exchange rate or CER). However, excluding the effects of recent acquisitions, the metric rose to 23.3% year over year (or up 2% at CER).
Research and development expenses increased 15.8% to $49.9 million (up 18% at CER). This, in turn, increased adjusted operating expenses by 8.1%, which amounted to $221.4 million. However, adjusted operating margin in the reported quarter expanded 209 bps to 29.6%.
Financial Updates
ResMed exited the second quarter of fiscal 2020 with cash and cash equivalents of $204.1 million compared with $172.2 million at the end of the first quarter.
Cumulative cash flow from operating activities was $232.3 million at the end of the second quarter compared with $177.6 million in the year-ago period.
Along with the earnings release, ResMed announced a regular quarterly dividend payout of 39 cents per share.
Our Take
The company exited second-quarter fiscal 2020 on a solid note, with earnings and revenues beating the Zacks Consensus Estimate. It is encouraging to note that ResMed registered growth at CER across both its key operating segments — Total Sleep and Respiratory Care, and Software-as-a-Service.
Mask sales were particularly strong in Europe and Asia. Within Software-as-a-Service, the company recorded continued momentum in the Brightree service portfolio and an additional contribution from the MatrixCare buyout.
However, in the quarter, device sales in France were impacted as customers completed their connected device upgrade programs.
Zacks Rank and Key Picks
ResMed currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are SeaSpine Holdings Corporation , STERIS plc (STE - Free Report) and DexCom, Inc. (DXCM - Free Report) , all these currently carry a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for SeaSpine’s fourth-quarter 2019 revenues is pegged at $43.6 million, suggesting 14.7% growth from the prior-year reported figure. The same for loss per share is anticipated at 44 cents, implying a 16.9% improvement from the year-ago reported number.
The Zacks Consensus Estimate for STERIS’s third-quarter fiscal 2020 revenues is pegged at $749.7 million, hinting at a 7.7% increase from the year-earlier reported figure. The same for adjusted earnings per share stands at $1.43, indicating a 13.5% rise from the year-ago reported figure.
The Zacks Consensus Estimate for DexCom’s fourth-quarter 2019 revenues is pegged at $457 million, suggesting 35.2% growth from the prior-year reported figure. The same for adjusted earnings per share stands at 72 cents, implying a 33.3% improvement from the year-earlier reported figure.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>